Pharmacogenomics: Is this the final chapter in the remarkable story of warfarin?

Journal of the American Medical Directors Association

Volumn 12, Issue 9, 2011, Pages 613-614

  Gurwitz, Jerry H ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; DICOUMAROL; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ANTICOAGULANT THERAPY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; EDITORIAL; GENETIC VARIABILITY; HUMAN; PHARMACOGENOMICS; THROMBOEMBOLISM;

EID: 82455209061     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2011.04.011     Document Type: Editorial

References (18)

1. Majerus P.W., Tollefsen D.M. Anticoagulant, thrombolytic and antiplatelet drugs. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2001, 1526. McGraw-Hill, New York, NY. 10th ed. J.G. Hardman, L.E. Limbird (Eds.).
2. Whitlon D.S., Sadowski J.A., Suttie J.W. Mechanism of coumarin action: Significance of vitamin K epoxide reductase inhibition. Biochemistry 1978, 17:1371-1377.
3. Shurin S.B., Nabel E.G. Pharmacogenomics-ready for prime time?. N Engl J Med 2008, 358:1061-1063.
4. Wang L., McLeod H.L., Weinshilboum R.M. Genomics and drug response. N Engl J Med 2011, 364:1144-1153.
5. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005, 352:2285-2293.
6. Higashi M.K., Veenstra D.L., Condo L.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002, 287:1690-1698.
7. Schwarz U.I., Ritchie M.D., Bradford Y., et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008, 358:999-1008.
8. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009, 369:753-764.
9. Safety Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER) - January 2010. Available at: Accessed March 27, 2011. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm201100.htm.
10. Schwartz J.B., Kane L., Moore K., Wu A.H.B. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin. J Am Med Dir Assoc 2011, 12:633-638.
11. Budnitz D.S., Shehab N., Kegler S.R., Richards C.L. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007, 147:755-765.
12. Gurwitz J.H., Field T.S., Harrold L.R., et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003, 289:1107-1116.
13. Gurwitz J.H., Field T.S., Radford M.J., et al. The safety of warfarin therapy in the nursing home setting. Am J Med 2007, 120:539-544.
14. Judge J., Field T.S., DeFlorio M., et al. Prescribers' responses to alerts during medication ordering in the long-term care setting. J Am Med Inform Assoc 2006, 13:385-390.
15. Field T.S., Tjia J., Mazor K.M., et al. Randomization of a warfarin communication protocol for nursing homes: An SBAR-based approach. Am J Med 2011, 124:179. e1-7.
16. Gurwitz J.H. Can anticoagulation care be improved with technology?. CMAJ 2009, 180:909-910.
17. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817.
18. Hylek E.M. Therapeutic potential of oral factor Xa inhibitors. N Engl J Med 2010, 363:2559-2561.